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In the  bone  tissue  engineering  ﬁeld,  there  is a growing  interest  in the  application  of  bioactive  glass  scaf-
folds  (45S5Bioglass®)  due  to their  bone  bonding  ability,  osteoconductivity  and  osteoinductivity.  However,
such  scaffolds  still  lack some  of  the  required  functionalities  to enable  the successful  formation  of  new
bone,  e.g.  effective  antibacterial  properties.  A  large  number  of  studies  suggest  that  selenium  (Se) has
signiﬁcant  role  in antioxidant  protection,  enhanced  immune  surveillance  and  modulation  of  cell  pro-
liferation.  Selenium  nanoparticles  (SeNp)  have  also  been  reported  to possess  antibacterial  as  well  as
antiviral  activities.  In  this  investigation,  uniform,  stable,  amorphous  SeNp  have  been  synthesized  and
additionally  immobilized  within  spherical  PLGA  particles  (PLGA/SeNp).  These  particles  were  used  to  coat
bioactive  glass-based  scaffolds  synthesized  by  the  foam  replica  method.  Samples  were  characterized  by
X-ray  diffraction  (XRD),  Fourier  transform  infrared  spectroscopy  (FTIR),  scanning  electron  microscopyntibacterial activity (SEM),  energy  dispersive  X-ray  spectroscopy  (EDS)  and  transmission  electron  microscopy  (TEM).  SeNp,
45S5Bioglass®/SeNp  and  45S5Bioglass®/PLGA/SeNp  showed  a considerable  antibacterial  activity  against
Gram  positive  bacteria,  Staphylococcus  aureus  and  Staphylococcus  epidermidis,  one of  the  main  causative
agents  of orthopedic  infections.  The  functionalized  Se-coated  bioactive  glass  scaffolds  represent  a new
family  of  bioactive,  antibacterial  scaffolds  for bone  tissue  engineering  applications.. Introduction
Bone tissue is the major structural and supportive connective
issue composed of about 25% water, 25% protein i.e. collagen ﬁbers,
nd 50% mineral salts of which the most calcium and phospho-
ous salts. It is a dynamic, highly vascularized tissue with the major
ole to provide structural support for the body [1]. The worldwide
ncidence of bone disorders and conditions signiﬁcantly increases
ecently and it is expected to double by 2020 [2]. The ﬁeld of bone
issue engineering was initiated a few decades ago and is based
n the understanding of bone structure, bone mechanics, and tis-
ue formation [1,2]. Bone tissue engineering aims to successfully
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regenerate or repair bone and applies methods from materials
engineering and life sciences to produce artiﬁcial or natural con-
structs [3,4]. There are several approaches for the regeneration or
for the formation of the new tissue. One is to isolate speciﬁc cells
from a patient and to grow them on a three-dimensional scaffold
after which the construct will be delivered to the desired site in
the patient’s body aiming to direct new tissue formation into the
scaffold [3]. Another way is to implant scaffold for tissue ingrowth
directly in vivo to stimulate and to direct tissue formation in situ
[3–5]. Biomaterials for scaffolds preparation have to possess cer-
tain physical, chemical, and biological properties [6–8]. However,
it is difﬁcult for any biomaterial to satisfy all of the requirements
which led to the development of wide variety of composites or
hybrid materials. These hybrid materials are made by combination
of two  or more biomaterials, with enhanced functionalities, in the
form of polymer–polymer blends, organic–inorganic hybrids and
polymer–ceramic composites [3,9–12]. Recently, there is a growing
interest in the application of bioactive silicate glasses due to their
bone bonding ability and osteoconductivity [13,14]. In addition,
faces 
t
a
s
b
s
f
e
o
a
n
t
o
t
p
O
u
d
n
d
a
i
c
c
[
i
o
[
a
e
o
f
r
t
g
i
[
b
b
(
s
s
n
(
e
(
r
b
d
n
f
r
a
2
2
p
F
G
sM. Stevanovic´ et al. / Colloids and Sur
hese highly surface reactive materials exhibit osteogenic and
ngiogenic effects [13]. Structural 3D bioactive glass scaffolds with
uitable interpenetrating porosity and mechanical stability have
een developed in recent years [14–16]. However such scaffolds
till lack some of the required functionalities to enable the success-
ul formation of new vascularized bone in critical size bone defects,
.g. enhanced bioactivity by incorporation of bioactive molecules
r growth factors and effective antibacterial properties. Addition-
lly, the angiogenic and antibacterial characteristics of scaffolds are
ow being examined in more detail, the goal being to integrate
hese functions in a bioactive scaffold with osteoconductive and
steoinductive properties [3,17–21].
Biodegradable and bioresorbable polymers such as polylac-
ide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA),
oly(epsilon-caprolactone) (PCL) are approved by the World Health
rganization and Food and Drug Administration and are very often
sed as materials in medicine and pharmacy as polymeric pro-
rugs, for drug delivery or therapeutic systems [22,23]. They have
umerous advantages, such as excellent processing characteristics,
egradation rates that can be tailored for the intended application,
s well as exhibiting unique pharmacokinetics and pharmacolog-
cal efﬁcacy [23]. PLGA micro and nanoparticles are used for the
ontrolled delivery of several classes of medicaments such as anti-
ancer agents, growth factors, antibiotics, antimicrobial agents, etc.
24]. Metal and metalloid nanoparticles are used in various biomed-
cal applications. For example, silver, gold and platinum are some
f the alternative inorganic materials with antimicrobial properties
25]. Selenium nanoparticles have also been reported to possess
ntibacterial as well as antiviral activities [26]. Additionally, sev-
ral ﬁndings suggest that selenium plays critical roles in a variety
f physiological processes and selenium intake may  be necessary
or bone health [26]. In a recent review, Zeng et al. have summa-
ized current knowledge of the effects of selenium on bone and
he underlying mechanisms [27]. Selenium deﬁciency can retard
rowth and alter bone metabolism [27–29]. Insufﬁcient selenium
ntakes have been associated with increased risk to bone disease
29].
The main idea of this work was to design and evaluate a new
ioactive material for bone tissue engineering applications, com-
ining bioactive glass (BG) scaffolds and selenium nanoparticles
SeNp), or poly(lactide-co-glycolide) particles with immobilized
elenium nanoparticles (PLGA/SeNp) applied as coatings on the BG
caffolds. 3D BG scaffolds were fabricated by the foam replica tech-
ique [15]. The samples were characterized by X-ray diffraction
XRD), Fourier transform infrared spectroscopy (FTIR), scanning
lectron microscopy (SEM), energy dispersive X-ray spectroscopy
EDS) and transmission electron microscopy (TEM). The antibacte-
ial activity of the samples was determined against Gram positive
acteria: Staphylococcus aureus (ATCC 25923), Staphylococcus epi-
ermidis (ATCC 1228), Bacillus subtilis (ATCC 6633), and Gram
egative: Klebsiella pneumoniae (ATCC 13883).
The present scaffold development corresponds to a growing
amily of bioactive glass-based scaffolds incorporating antibacte-
ial, functional coatings [12,30–34] although combination of SeNp
nd BG has not been investigated previously.
. Materials and methods
.1. Materials
For the scaffold fabrication, 45S5Bioglass® powder with a com-
osition: 45 SiO2, 24.5 CaO, 24.5 Na2O, 6 P2O5 in wt%, was used.
ully hydrolyzed PVA (Mw  approx. 30,000) (Merck, Darmstadt,
ermany) was used to prepare the Bioglass® slurries to make
caffolds. Polyurethane (PU) foam (Eurofoam Deutschland GmbH)B: Biointerfaces 132 (2015) 208–215 209
with 60 ppi (pores per inch) was used as a template to fabricate
scaffolds by the foam replica method described elsewhere [15].
Poly(d,l-lactide-co-glycolide) (PLGA) was  obtained from Durect,
Lactel, Adsorbable Polymers International and had lactide to
glycolide ratio of 50:50. Molecular weight of polymer was
40,000–50,000 g/mol. Polyvinyl pyrrolidone (povidone, PVP) was
obtained from Merck Chemicals Ltd. (k-25, Merck, Germany). For
the preparing SeNp, sodium selenite (Na2SeO3) as well as bovine
serum albumin (BSA) were obtained from Sigma–Aldrich, St. Louis,
MO.  Ascorbic acid was  purchased from Microvit, Adisseo, USA
(C6H8O6, 176.13 g/mol). All other chemicals and solvents were of
reagent grade.
2.2. Methods
2.2.1. Synthesis of bioactive glass scaffolds
BG scaffolds were prepared by the foam replica method accord-
ing to the process introduced earlier [15]. Brieﬂy, glass powder was
dispersed in the solution of polyvinyl alcohol (PVA) in deionized
water and under constant stirring. In such obtained slurry, PU foams
were immersed so that the foam struts were coated with glass par-
ticles. PU foam was  used as template in this replication method
and it was  cut into 20 × 10 × 10 mm3 samples. After drying at room
temperature, the as-coated foams were slowly burned out in order
to minimize damage to the glass coating and then the glass network
(scaffold) was sintered by heat treatment at 1100 ◦C [15].
2.2.2. Synthesis of selenium nanoparticles (SeNp)
In the synthesis of SeNp, ﬁrstly 217 mg  of ascorbic acid have
been dissolved in 10 mL distilled water and afterward 12.5 mL  of
0.02 M sodium selenite was added into the solvent mixture. The
formation of selenium nanoparticles was immediately visualized
by a color change of the reactant solution from the colorless to
orange. Simultaneously with the addition of sodium selenite, 5 mL
of BSA was dropwise added into the solution to stabilize particles
i.e. to form BSA-capped SeNp.
2.2.3. Synthesis of PLGA particles with immobilized selenium
nanoparticles (PLGA/SeNp)
PLGA/SeNp microspheres were produced using a physicochem-
ical solvent/nonsolvent method. First of all, SeNp were prepared as
described above. Afterward, PLGA commercial granules (220 mg)
were dissolved in 20 mL  acetone over approximately 2 h at room
temperature. Then, the solution containing SeNp (0.5 mL)  was
added to a solution of PLGA in acetone, continuously being homog-
enized at 21,000 rpm during 15 min, with the resulting solution
becoming slightly orange. PLGA/SeNp precipitated by the addi-
tion of ethanol (60 mL)  and the solution became whitish. Thus
obtained solution was very slowly poured into 40 mL  of aqueous
PVP solution (0.5% w/w)  while continuously stirring at 500 rpm by
a stirrer. Using PVP as the stabilizer, negative charged PLGA/SeNp
particles are produced, i.e. with speciﬁc zeta potential, which pre-
vents their agglomeration. Zeta potential of the PLGA/SeNp was
measured by Zetasizer Nano ZS particle analyzer (Model ZEN3600,
Malvern Instruments, Malvern, UK) and it was determined to be
−30.1 ± 0.5 mV.
2.2.4. Coating of 45S5Bioglass® scaffolds by SeNp or by
PLGA/SeNp
Sintered 45S5Bioglass® scaffolds were coated with SeNp or
with PLGA/SeNp (Fig. 1). The coating was performed by simple
soaking/immersing the scaffolds into solution containing SeNp or
into solution containing PLGA/SeNp microspheres. This was  done
with the help of a copper wire gently entwined in the pores
of the scaffold. The scaffolds were immersed during the 5 min
while continuously stirring at 100 rpm. The coated scaffolds were
210 M. Stevanovic´ et al. / Colloids and Surfaces 
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aig. 1. Schematic diagram showing the steps involved in the coating of
5S5Bioglass® by SeNp or by PLGA/SeNp.
eft to dry at room temperature and ambient pressure. Weight
ercentage of coating on BG scaffolds was determined by thermo-
ravimetric analysis from room temperature to 1000 ◦C (SETSYS
vo TG-DTA/DSC, Seteram Instrumentation, Lyon, France), with
eating rate of 10 ◦C/min. Precise data was obtained by recording
G curves of uncoated BG scaffolds, SeNp, PLGA and PLGA/SeNp, as
ell as BG scaffolds coated with SeNp and PLGA/SeNp. Coating of
eNp on BG scaffolds was estimated to be 2.5 wt%, while coating of
LGA/SeNp on BG scaffold was 1.18 wt%. Loading of SeNp in PLGA
as 0.15 wt%.
.3. Characterization
.3.1. X-ray diffraction
For X-ray diffraction analysis, the samples were ﬁrstly grindednd powdered. For identiﬁcation of the phase composition (phase
nalysis) of the uncoated scaffolds or scaffolds coated by SeNp
r by PLGA/SeNp, X-ray diffraction was used, with a Philips
W 1050 diffractometer with Cu-K1,2 radiation (Ni ﬁlter). The
ig. 2. X-ray diffraction patterns of commercial BSA used in the synthesis for capping S
nd  45S5Bioglass®/PLGA/SeNp. The c stands for combeite.B: Biointerfaces 132 (2015) 208–215
measurements were carried out in the 2 range of 10◦–70◦, with
a scanning step width of 0.05◦, and 2 s per step.
2.3.2. Fourier-transform infrared spectroscopy (FTIR)
The quality analysis of the 45S5Bioglass® scaffolds coated by
SeNp or by PLGA/SeNp was further performed with FTIR spec-
troscopy. FTIR spectra of the samples were recorded in the range of
400–4000 cm−1 using a NicoletTM iSTM50 FT-IR Spectrometer. FTIR
measurements of the samples were carried out to identify the pos-
sible interactions between the surface of the BG scaffolds and SeNp
or interactions between BG and PLGA/SeNp.
2.3.3. Scanning electron microscopy (SEM)
To analyze the microstructures of the 45S5Bioglass® scaffolds
coated by SeNp or by PLGA/SeNp, scanning electron microscopy
(SEM) was  carried out, on a JEOL-JSM-6610LV instrument. The sam-
ples for SEM analysis were coated with gold using the physical
vapour deposition (PVD) process. Samples were covered with gold
(Leica SCD005 sputter coater), using 30 mA  current from the dis-
tance of 50 mm during 180 s. The gold coating was used to prevent
their charging.
2.3.4. Energy dispersive spectroscopy (EDS)
Energy dispersive spectroscopy (EDS) (model: X-Max Large Area
Analytical Silicon Drift connected with INCA Energy 350 Micro-
analysis System) was  used for the elemental characterization of
45S5Bioglass®/SeNp and 45S5Bioglass®/PLGA/SeNp scaffolds.
2.3.5. Transmission electron microscopy (TEM)
Transmission electron microscopy using a JEOL JEM-1400plus
instrument provided further morphological characterization of the
SeNp incorporated within the PLGA particle, based on the explo-
ration of the individual microstructures.2.3.6. Antibacterial activity
The antibacterial activities of the tested compounds were inves-
tigated against Gram positive bacteria: S. aureus (ATCC 25923),
S. epidermidis (ATCC 1228), B. subtilis (ATCC 6633), and Gram
eNp, as-prepared SeNp, PLGA/SeNp, uncoated 45S5Bioglass® , 45S5Bioglass®/SeNp
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egative: K. pneumoniae (ATCC 13883). A broth microdilution
ethod was used to determine minimum inhibitory concentra-
ions (MICs) of samples. MIC  represents the lowest concentration
f a compound at which the microorganism does not demonstrate
isible growth. MICs were determined according to Clinical and
aboratory Standards Institute (CLSI 2005) [35]. Tests were per-
ormed in Müller Hinton broth. Overnight broth cultures were
repared for each strain, and the ﬁnal concentration in each well
as adjusted to 2 × 106 CFU/ml. Uncoated 45S5Bioglass® scaffolds
®s well as 45S5Bioglass scaffolds coated by SeNp or by PLGA/SeNp
ere crushed into powder and then a serial doubling dilutions in
% dimethylsulfoxide were prepared. A serial doubling dilution
f the compounds were prepared in Müller–Hinton broth, in a
ig. 4. SEM images showing typical (A) pore (bars 1 mm and 500 m)  and (B) strut mi
epresentative images of the scaffold cross-sections.B: Biointerfaces 132 (2015) 208–215 211
96-well microtiter plate, over the range of 1000–12.5 g/ml. In the
tests, 0.05% triphenyl tetrazolium chloride (TTC, Aldrich Chemical
Company Inc., USA) was  also added to the culture medium as a
growth indicator. As a positive control of growth, wells containing
only the microorganisms in the broth were used. Bacteria growth
was determined after 24 h of incubation at 37 ◦C. All of the MIC
determinations were performed in duplicate, and two  positive
growth controls were included.
3. Results and discussion
X-ray diffractograms of samples (commercial BSA used in
the synthesis for capping SeNp (given here just for comparison
purposes), SeNp, PLGA/SeNp, uncoated 45S5Bioglass® scaffolds,
45S5Bioglass® scaffolds coated by SeNp and 45S5Bioglass® scaf-
folds coated by PLGA/SeNp) are shown in Fig. 2.
P2O5, Na2O, CaO and SiO2 are the main components of
45S5Bioglass®. The ratio between them is very important con-
sidering bioactive character of the material. 45S5Bioglass®
is glass where 45 is the weight percentage of SiO2 and 5 is
the molar ratio of Ca to P. Depending on the thermal treat-
ment, bioactive glass powders exhibit different degrees of
crystallinity [15,36]. The narrow peaks with high intensity indicate
high degree of crystallinity of 45S5Bioglass® scaffold (Fig. 2).
PLGA, as well as SeNp, did not exhibit any crystalline peaks
because of their amorphous nature (Fig. 2). The only difference
between X-ray diffraction patterns of uncoated 45S5Bioglass®,
45S5Bioglass®/SeNp, and 45S5Bioglass®/PLGA/SeNp scaf-
folds is in peak which belongs to BSA which is used in the
synthesis of SeNp as a capping agent. X-ray diffraction pat-
terns of uncoated 45S5Bioglass® as well as 45S5Bioglass®/
SeNp scaffolds, and 45S5Bioglass /PLGA/SeNp scaffolds
showed only two  phases, both belonging to the family
of combeites (c) (Fig. 2) [37]. These phases are low-
(Na4.2Ca2.8(Si6O18)) and high-combeite (Na15.78Ca3(Si6O12))
crostructures (bars 1 m) of a 45S5Bioglass® scaffold coated by SeNp. These are
212 M. Stevanovic´ et al. / Colloids and Surfaces B: Biointerfaces 132 (2015) 208–215
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37]. From the literature is known that 45S5Bioglass® has a higher
ndex of bioactivity than hydroxyapatite [38] and bioactivity has
een shown to be reduced but not suppressed by crystallization
f the phase Na2Ca2Si3O9, as found by Clupper and Hench, which
howed amorphous calcium phosphate formation on its surface
hen it was contacted with simulated body ﬂuid (SBF) [39].
he other crystalline phases, namely Na4Ca4Si6O18 also exhibits
ioactivity because of its similarity to the phase Na2Ca2Si3O9
36,37]. Na4Ca4Si6O18 and Na15Ca3.84Si12O36 phases can be con-
idered as forerunner phases for low- (Na4.2Ca2.8(Si6O18)) and
igh-combeite (Na15.78Ca3(Si6O12)), respectively [37] meaning
hat 45S5Bioglass®/SeNp, and 45S5Bioglass®/PLGA/SeNp scaffolds
re also bioactive.
The FTIR spectra of the 45S5Bioglass®/SeNp and
5S5Bioglass®/PLGA/SeNp samples are shown in Fig. 3. FTIR
pectroscopy of these samples was performed to ascertain the
resence of SeNp or PLGA/SeNp on the scaffolds. As observed,
oth spectra reveal bands at 3292 cm−1, 2654 cm−1, 1056 cm−1,
036 cm−1, 940 cm−1, 701 cm−1, 616 cm−1 and 524 cm−1. The
road band at 3292 cm−1 is attributed to OH− absorption. The
and at 1036 cm−1 is associated with P O vibrational mode
40,41] while the band at 940 cm−1 is attributed to CH2 out-of-
lane wag [42]. In the spectra of 45S5Bioglass®/PLGA/SeNp the
and at 1744 cm−1 is associated with C O group and 1581 cm−1
nd 1456 cm−1 are associated with C H group (in CH3 and
CH2) [42]. In the spectra of 45S5Bioglass®/SeNp the band
t 1580 cm−1 corresponds to the NH2 deformation (amide II® scaffold, with EDS results on a selected areas of the sample.
band) [42]. Apart from those peaks, no other peaks can be
identiﬁed.
The microstructures of the prepared 45S5Bioglass®/SeNp scaf-
folds were examined by SEM (Fig. 4). The images were taken from
the interior section of the scaffolds. A highly porous structure and
tailored pore shape for speciﬁc application, i.e. bone defects, are
essential requirements for ideal bone scaffolds. From these SEM
images it can be seen that 45S5Bioglass®/SeNp scaffolds have a
well interconnected porous structure. The pore size of the scaf-
fold is around 500 m (Fig. 4). At higher magniﬁcation on the strut
microstructures of a 45S5Bioglass®/SeNp scaffold, it is visible that
the strut is coated by SeNp. SeNp particles on the strut are spherical,
fairly uniform and agglomerated.
Fig. 5 shows a SEM micrograph of a SeNp-coated 45S5Bioglass®
scaffold, with EDS results on a selected area of the sample. A surface
elemental composition analysis of the SeNp-coated 45S5Bioglass®
scaffold showed a strong selenium atom signal, along with silicon,
calcium, sodium, oxygen, phosphorus and carbon. In the spec-
tra, there are also peaks which belong to gold and this is due
to the preparation of the samples for SEM and EDS measure-
ments, i.e. the samples were coated with gold using the physical
vapour deposition process. No obvious peaks for other elements
or impurities were observed in the spectra. These results fur-
ther conﬁrm the successful coating of 45S5Bioglass® scaffold with
SeNp.
Representative SEM images of 45S5Bioglass®/PLGA/SeNp scaf-
folds are given in Fig. 6. These SEM images show typical pore
M. Stevanovic´ et al. / Colloids and Surfaces B: Biointerfaces 132 (2015) 208–215 213
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fig. 6. Representative SEM images (A) of 45S5Bioglass®/PLGA/SeNp scaffolds show
caffold coated by PLGA/SeNp. TEM image (B) of PLGA/SeNp particle from 45S5Biog
bars  500 nm).
nd struts microstructures of a 45S5Bioglass® scaffold coated by
LGA/SeNp. From these images, it can be seen that in the case of
5S5Bioglass®/PLGA/SeNp scaffolds pores are less uniform com-
ared to 45S5Bioglass®/SeNp scaffolds. PLGA/SeNp particles are
pherical in shape and with sizes around 1 m or less. It is apparent
hat in both cases the coatings reduce the porosity of scaffolds how-
ver given the large size of pores in the as-fabricated scaffolds, the
oated samples still exhibit a suitable pore structure (not quantiﬁed
n this study). Fig. 6 shows also a TEM image of PLGA/SeNp particle
rom a 45S5Bioglass® scaffold strut showing heterogeneously dis-
ributed SeNp within the PLGA polymer matrix. SeNp particles are
pherical-shaped.
Energy dispersive spectroscopy was also used for the sur-
ace elemental composition analysis of the 45S5Bioglass® scaffoldical pore (bars 500 m) and strut (bars 10 m)  microstructures of a 45S5Bioglass®
strut showing heterogeneously distributed SeNps within the PLGA polymer matrix
coated with PLGA/SeNp. The EDS spectra showed that the main
elements of the 45S5Bioglass®/PLGA/SeNp scaffolds are carbon,
oxygen, calcium, sodium and silicon (Fig. 7). Peaks which belong
to selenium are also present in the spectra. Peaks of gold were
from the sputter coated layer. No peaks for other elements
or impurities were observed in the spectra. The EDS analy-
sis of the PLGA/SeNp coated 45S5Bioglass® scaffold showed a
much more intense presence of carbon and oxygen compared to
45S5Bioglass®/SeNp scaffold (Fig. 5) thus indicating the coating of
scaffold by PLGA/SeNp.The antimicrobial activity of the samples SeNp,
45S5Bioglass®/SeNp, 45S5Bioglass®/PLGA/SeNp and uncoated
45S5Bioglass® scaffolds was  examined. Minimal inhibitory concen-
trations of samples were determined using a broth microdilution
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ssay against Gram positive bacteria: S. aureus (ATCC 25923),
. epidermidis (ATCC 1228), B. subtilis (ATCC 6633), and Gram
egative: K. pneumoniae (ATCC 13883) (Fig. 8).
Hospital-acquired infections (nosocomial infections – not
resent nor incubating at admission) are caused by bacteria and
ig. 8. Antibacterial activity of SeNp, 45S5Bioglass®/SeNp, 45S5Bioglass®/
LGA/SeNp and uncoated 45S5Bioglass® . Minimal inhibitory concentrations of sam-
les were determined using a broth microdilution assay against Gram positive
acteria: Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC
228), Bacillus subtilis (ATCC 6633), and Gram negative: Klebsiella pneumoniae (ATCC
3883).p scaffold, with EDS results on selected areas of the sample.
other pathogens and the most common of these infections are infec-
tions associated with orthopedic devices and surgical implants.
Infections that are associated with a variety of surgical implants
have clinical and economic consequences and often result in seri-
ous disabilities [43]. Staphylococcus is a group of bacteria and,
while S. epidermidis is not usually pathogenic, S. aureus is con-
sidered to be the most dangerous in this group. It can cause a
number of diseases and infections range from mild to life threaten-
ing. However, even S. epidermidis, such as B. subtilis,  could cause
serious infections in patients with compromised immune sys-
tems. The Gram-negative bacteria, K. pneumoniae also may colonize
sites when the host defenses are compromised and cause a vari-
ety of lung, bone, heart and bloodstream infections [44]. All of
them may be highly resistant to traditional antibiotic therapies
[25,45].
From the literature is known that selenium nanoparticles are
very important for bone health [27,28] but also could serve as
antibacterial agent. The role of SeNp as antibacterial agent has been
supported in several recent studies [26,46,47].
Results of this study (Fig. 8) provided the evidence of a con-
siderable antibacterial activity against S. aureus (ATCC 25923)
and S. epidermidis (ATCC 1228), in the presence of SeNp as
well as in the presence of samples 45S5Bioglass®/SeNp and
45S5Bioglass®/PLGA/SeNp. SeNps also inhibited growth of B. sub-
tilis and K. pneumoniae.
In the literature, several mechanisms by which nanoparticles
may  exhibit antimicrobial activity have been proposed [48,49].
Nanoparticles may  express better antimicrobial activity compared
to conventional preparations due to their large surface-to-mass
ratio, better penetration through the cell membrane to affect the
intracellular processes from the inside, surface charge, etc. A better
understanding of the antibacterial activity of SeNp would require
a proper investigation of the membrane-bound and intracellular
nanoparticles.
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